VBI Vaccines Inc. (VBIV)
NASDAQ: VBIV · IEX Real-Time Price · USD
0.557
-0.007 (-1.33%)
Apr 30, 2024, 10:08 AM EDT - Market open

VBI Vaccines Revenue

In the year 2023, VBI Vaccines had annual revenue of $8.68M with 702.40% growth. Revenue in the quarter ending December 31, 2023 was $853.00K with 191.13% year-over-year growth.

Revenue (ttm)
$8.68M
Revenue Growth
+702.40%
P/S Ratio
1.85
Revenue / Employee
$66,275
Employees
131
Market Cap
15.80M USD

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 20238.68M7.60M702.40%
Dec 31, 20221.08M451.00K71.47%
Dec 31, 2021631.00K-430.00K-40.53%
Dec 31, 20201.06M-1.16M-52.23%
Dec 31, 20192.22M-1.13M-33.80%
Dec 31, 20183.36M2.49M287.86%
Dec 31, 2017865.00K317.00K57.85%
Dec 31, 2016548.00K-407.00K-42.62%
Dec 31, 2015955.00K-1.91M-66.70%
Dec 31, 20142.87M1.21M72.67%
Dec 31, 20131.66M1.05M172.01%
Mar 31, 2012610.65K568.65K1,354.06%
Mar 31, 201142.00K41.24K5,455.03%
Mar 31, 2010756.00-8.36K-91.71%
Mar 31, 20099.12K-2.46K-21.25%
Mar 31, 200811.58K-2.49K-17.71%
Mar 31, 200714.07K2.61K22.72%
Mar 31, 200611.47K11.05K2,623.52%
Mar 31, 2005421.00525.00-504.81%
Mar 31, 2004-104.00-829.00-114.34%
Mar 31, 2003725.00-86.00-10.60%
Mar 31, 2002811.00--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
CareCloud 117.06M
Aytu BioPharma 98.50M
Meihua International Medical Technologies Co. 97.10M
PAVmed 2.45M
Talis Biomedical 2.13M
Avalo Therapeutics 1.92M
Traws Pharma 226.00K
Revenue Rankings